A new technology can make nanoscale protein measurements - which may mean understanding the effects of therapeutic agents in tumor cells and different cell populations within patients, a key step toward being able to tailor therapy for each patient.

Currently, research on cancer agent activity requires patients to undergo several invasive biopsies to generate enough cells for testing.   A group of researchers have developed a highly sensitive test called the nano-immunoassay (NIA) that can make nanoscale protein measurements in cells from minimally invasive blood draws or fine-needle aspirates. The researchers used a microfluidic instrument called the Nanopro1000.